Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EPC stock price vs BMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Needs BMY P/E.
Implied fair value · at EPC's multiple
Needs EPC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EDGEWELL PERSONAL CARE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
EPC vs PG
COLGATE PALMOLIVE CO
EPC vs CL
CHURCH & DWIGHT CO INC /DE/
EPC vs CHD
COTY INC.
EPC vs COTY
Pfizer Inc.
EPC vs PFE
Merck & Co., Inc.
EPC vs MRK
AbbVie Inc.
EPC vs ABBV
Eli Lilly and Company
EPC vs LLY
Amgen Inc.
EPC vs AMGN
Gilead Sciences, Inc.
EPC vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EPC can sustainably expand margins and reduce leverage from 5.0x net debt/EBITDA while avoiding further revenue deterioration, then consider holding; otherwise the valuation and quality data argue for avoiding new long exposure because the current price implies far more earnings quality than EPC is delivering.
EPC trades at 51.3x P/E versus BMY at 18.9x, despite EPC generating far smaller profits and lower margins. The implied price of $10.00 versus the current $27.19 suggests 63.2% downside, while the stock is also above its historical band and DCF range.
Supporting Metrics
